The Rel/NF-B family of transcription factors is key for immune and inflammatory responses and also controls cell proliferation and apoptosis. The v-Rel oncoprotein of reticuloendotheliosis virus strain T (Rev-T) is the most potent oncogenic member of this family. Both v-Rel and its cellular homologue c-Rel transform primary splenic lymphocytes in vitro and cause fatal leukemia/lymphomas in chickens and transgenic mice (5, 9, 17, 22, 23, 33, 38, 39) . This agrees with the implication of Rel/NF-B in the pathogenesis and chemoresistance of many hematopoietic and solid tumors, including primary mediastinal B-cell lymphomas (PMBCL) and classical Hodgkin's lymphoma, in which constitutively high levels of nuclear c-Rel protein are necessary for tumor cell survival and proliferation (3, 4, 14, 18, 20, 27, 49) . Additionally, some PMBCL and follicular lymphomas harbor c-rel gene mutations that decrease c-Rel's transactivation potency and enhance its transforming activity in primary chicken lymphocytes (45) . This is consistent with the increased transforming phenotype conferred by certain mutations in v-Rel and c-Rel and indicates that modulation of Rel's transcriptional activity can significantly affect its oncogenicity (12, 43, 44) .
The Rel proteins bind to B DNA sites as homo-or heterodimers with other NF-B family members via their N-terminal Rel homology domain (RHD), which also mediates nuclear localization and association with inhibitory IB subunits. Their C-terminal regions carry transactivation domains (TADs) that control cellular gene expression. Analyses focusing on the effects of v-Rel and c-Rel proteins on cellular gene expression have provided important insights into the mechanisms by which Rel/NF-B is involved in cancer (reviewed in reference 18). Studies revealed that their C-terminal TADs greatly influence their transforming potential in primary lymphocytes. While RelA failed to transform chicken lymphoid cells on its own, replacement of RelA's TAD with that of either v-Rel or c-Rel conferred a strong transforming phenotype both in vitro and in vivo (13) . Recent work showed that in addition to activating expression of antiapoptotic and proproliferative genes, the Rel TADs can also lead to gene-specific transcriptional repression of genes such as those for SH3BGRL and the B-cell receptor signaling molecules BCAP and BLNK, and this activity is as important for lymphocyte transformation by v-Rel as is its transactivation function (19, 35) . Additionally v-Rel can promote expression and alternative splicing of telomerase reverse transcriptase (TERT), which is also involved in lymphocyte transformation (24) . However, little is known about the cellular factors that associate with the Rel TADs and that modulate its transcriptional and oncogenic activities.
Here we report that coactivator of activating protein-1 (AP-1) and estrogen receptors (CAPER␣), also known as RNA-binding region (RNP1 or RRM) containing protein 2 (RNPC2), RNA-binding motif protein 39 (RBM39), or hepatocellular carcinoma 1.4 (HCC1.4), interacts with the v-Rel TAD (vTAD) and strongly modulates its transcriptional and transforming activities. Originally cloned as an autoantigen in a patient with liver cirrhosis that progressed to hepatocellular carcinoma (25) , CAPER␣ was previously described as a specific coactivator for JUN/AP-1 and estrogen receptors alpha and beta (ER␣ and ER␤) that also interacts with transcriptional coactivator ASC-2 (NCoA6) (26) . CAPER␣ shares homology with the SR family splicing factors U2AF 65 and PUF60 (11) and was also implicated in steroid hormone receptormediated alternative splicing, although its abilities to modulate transcription and alternative splicing are distinct and separable (11) . Our studies show that CAPER␣ is a novel transcriptional coregulator for v-Rel that strongly suppresses its transforming activity, uncovering a tumor suppressor role for CAPER␣ in regulating Rel's oncogenic activity.
Cell culture, transfection, and luciferase assays. The 293T human embryonic kidney cell line, primary chicken embryo fibroblasts (CEFs), v-Rel-transformed chicken spleen cells (CSC), and the DT40 chicken pre-B-cell line were cultured as described previously (12, 19) . Luciferase assays were performed with extracts from 293T cells (1 ϫ 10 6 ) transfected with calcium phosphate using a total of 6.01 g DNA, including 0.01 g of hRL-null Renilla luciferase DNA as a control, as described previously (12) . Extracts were prepared at 48 h posttransfection and analyzed for protein concentration and dual-luciferase activity (Promega Corp., Madison, WI).
GST pull-down, coimmunoprecipitation, and Western blot analyses. Extracts from 293T cells transfected with Rel expression vectors using Lipofectamine 2000 (Invitrogen) were prepared at 48 h posttransfection, quantitated for equal protein amounts, and used in GST pull-down assays with GST-CAPER␣ as described previously (40) in buffers supplemented with 10 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, 10 mM p-nitrophenyl phosphate, 10 mM sodium molybdate, 10 mM ␤-glycerophosphate, 10 mM benzamidine, and fresh 1ϫ Complete protease inhibitor cocktail (Boehringer-Mannheim/Roche), followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting.
Coimmunoprecipitation assays were carried out with extracts from 293T cells (3.5 ϫ 10 6 to 4 ϫ 10 6 cells) cotransfected with 6 g each of pCMV-v-Rel or pcDNA3.1-HisC-Xpress-CAPER␣ and either pcDNA3.1-CAPER␣-Flag, ⌬vRID-Flag, N-CAPER␣-Flag or Flag-Mcl-1 control using Lipofectamine 2000 (Invitrogen) or with extracts from v-Rel-transformed CSCs (10 7 cells). Cell lysates (1 mg) prepared at 48 h posttransfection were immunoprecipitated as described previously (30) with anti-v-Rel N-terminal antibody no. 1967 (50) , preimmune serum, anti-CAPER␣ (BL462; Bethyl Laboratories), or anti-FlagM2 (Sigma) and protein A/G Sepharose (Amersham Biosciences), followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting with antibodies to Flag, Rel, or Xpress and enhanced chemiluminescence (Amersham-Pharmacia). Other extracts used for immunoblotting were prepared in EBC lysis buffer (50 mM Tris [pH 8.0], 120 mM NaCl, 0.5% NP-40, 10% glycerol) containing 1ϫ Complete protease inhibitor cocktail. Antibodies for immunoblotting were against human CAPER␣ (BL462; Bethyl Laboratories), the RHD (SC-6955; Santa-Cruz Biotechnology), v-Rel (no. 1967) (50), Xpress and Myc (Invitrogen), Flag (F-3165; Sigma), GFP (TP401; Torrey Pines Biolabs), c-Jun (SC-45; Santa-Cruz Biotechnology), or actin (Sigma).
Transformation of primary splenic lymphocytes. CSCs were transformed with virus harvested from CEFs cotransfected with retroviral vectors coexpressing enhanced GFP (EGFP), Xpress-vRID, or CAPER␣-Flag along with v-Rel in pUCpJD214-IRES2-v-Rel, as described previously (19) . Cells (5% input) were seeded in soft agar, and transformed colonies were scored after 2 weeks. The remaining cells were used for Western blotting to verify protein expression. The results of three experiments were calculated as mean Ϯ standard deviation. Animals were used according to the National Cancer Institute Animal Care and Use Committee guidelines under an approved animal study protocol.
siRNA-mediated knockdown and RT-PCR. Small interfering RNA (siRNA) oligonucleotides for chicken CAPER␣ (GenBank accession number XM_425690) were designed with the pSicoOligomaker 1.5 program (48), synthesized, and annealed (siRNA no.233 sense [ATGATTTCTGATAGAAATT] and antisense [GGATGATTTCTGATAGAAATT] [Ambion]). CAPER␣ siRNA no. 233 (2.25 g) or an siRNA negative control (Ambion, NC 1) was electroporated into v-Rel-transformed CSCs (10 5 ) using Ambion's siPORT electroporation kit at 400 V and 1 F with a GenePulser (Bio-Rad). Electroporation of a Cy3-labeled control siRNA estimated 97.5% transfection efficiency as determined by flow cytometry. At 72 h postelectroporation, cells were analyzed by RT-PCR using primers CGTGGATCCGCCACCATGGGATATGGATTTATTACATTT TCTG and ATAAGAATGCGGCCGCTATCACATTAACTGAAGACGACC (24 cycles). v-Rel-transformed CSCs and control avian leukosis virus (ALV)-transformed DT40 chicken pre-B cells (10 5 ) were electroporated with chicken CAPER␣ siRNA no. 233 as described above, and 10 4 cells were seeded into soft agar. Transformed colonies were scored after 2 weeks.
RESULTS
CAPER␣ is a novel vTAD-interacting factor. To better understand how protein interactions with the Rel TADs influence the potent transforming activity of v-Rel, we screened a human pre-B-cell leukemia cDNA library fused to an N-terminal Myr tag for factors that could interact with a vTAD bait, using a modified cytosolic yeast two-hybrid screen (6) . In this system, interaction of a Myr-tagged cellular protein with the vTAD bait fused to amino acids 1 to 61 of constitutively active Ras confers membrane localization to Myc-Ras(61)-vTAD, allowing survival of the Cdc25-2 temperature-sensitive strain of S. cerevisiae at the restrictive temperature (37°C). Screening of 3 ϫ 10 5 colonies yielded 372 colonies, which represented 24 potential target cDNAs based on growth on Gal-ULM conditional medium at the restrictive temperature. Eleven cDNAs showed specific interaction with Myc-Ras(61)-vTAD. These corresponded to five different interacting candidates as determined by DNA sequence analysis. This study focuses on one of them, CAPER␣, which was previously described as a specific transcriptional coactivator for AP-1 and steroid hormone receptors (11, 26) .
CAPER␣ was isolated five times in the screen with the Myc-Ras(61)-vTAD bait and in overlapping fragments. Four of these spanned amino acids 310 to 530 of CAPER␣, and the other spanned amino acids 116 to 359. GST pull-down assays confirmed interaction of v-Rel with GST-CAPER␣ (Fig. 1A , lanes 1 to 5), similar to its previously reported interaction with GST-TBP (lane 4) (50) . GST-CAPER␣ also interacted with c-Jun, consistent with prior studies (lanes 6 to 8) (26) . In contrast, it failed to associate with a Myc-Bfl-1 negative control (lanes 9 to 11). The fact that GST-CAPER␣ could associate with a hybrid protein comprised of the N-terminal RHD of RelA fused to the vTAD (RelA-vRel) but failed to pull down the N-terminal RHD of v-Rel confirmed that CAPER␣ interacts with the C-terminal TAD of v-Rel (Fig. 1B , compare lanes 1 to 3 and 7 to 9 with lanes 4 to 6). Similar to its interaction with v-Rel, GST-CAPER␣ could also associate with the cellular NF-B family proteins mouse c-Rel, human c-Rel, and human RelA (Fig. 1C) .
Coimmunoprecipitation assays verified the interaction of vRel with CAPER␣, as seen by coimmunoprecipitation of v-Rel produced by in vitro translation with Xpress-tagged CAPER␣ fragments 6 and 17 isolated in the yeast two-hybrid screen (amino acids 116 to 359 and 310 to 530) ( Fig. 2A, lanes 1 to 4;  Fig. 4A ). v-Rel similarly associated with CAPER␣-Flag in vivo as seen by immunoprecipitation of transiently transfected 293T cells with anti-v-Rel followed by immunoblotting with antiFlag (lanes 5 to 8) and, conversely, by immunoprecipitation with anti-CAPER␣ followed by immunoblotting with an anti-RHD antibody (lanes 9 to 12).
Since antibodies to human CAPER␣ could detect endogenous chicken CAPER␣ by immunoblotting of CEFs and of v-Rel-transformed CSCs (Fig. 2B) , we investigated their interaction in v-Rel-transformed CSCs. Interestingly, coimmunoprecipitation assays with anti-CAPER␣ failed to show a significant interaction between endogenous chicken CAPER␣ and endogenous v-Rel in v-Rel-transformed CSCs compared to the immunoglobulin G (IgG) control (Fig. 2C , compare lanes 4 and 3). This suggests that if these proteins interact endogenously in v-Rel-transformed CSCs, their interaction is very weak, and it raises the possibility that CAPER␣ might negatively influence v-Rel's biological activity (see below).
CAPER␣ coactivates v-Rel-mediated transcription. Since CAPER␣ was described as a selective coactivator for transcription factors AP-1 and estrogen receptors (26) , its association with the v-Rel TAD led us to investigate its effect on v-Relmediated transcription. Consistent with its interaction with c-Jun, CAPER␣ efficiently synergized transactivation of a 4ϫ AP-1-luciferase reporter by c-Jun and c-Fos (Fig. 3A) . Enhancement of basal AP-1-luciferase activity most likely resulted from CAPER␣ effects on endogenous AP-1 complexes. Importantly, CAPER␣ strongly enhanced v-Rel-mediated activation of an IL-6-B-luciferase reporter by approximately eightfold, in contrast to CAPER␣ alone (Fig. 3B ). Since overexpression of CAPER␣-Flag did not affect the expression levels of v-Rel (Fig. 3C ), these data suggest genuine transcriptional synergy between CAPER␣ and v-Rel. This synergy was greatly reduced by coexpression of a dominant inhibitor of NF-B (IB␣M), indicating that the ability of CAPER␣ to enhance IL-6-B-luciferase expression is Rel/NF-B dependent (Fig. 3D ). In contrast, CAPER␣ failed to enhance E2F1-mediated transcriptional activation of a p73-luciferase reporter (Fig. 3E ). This is consistent with previous work showing that CAPER␣ is not a general transcriptional coactivator but rather is selective for certain transcription factors such as AP-1 and ER␣/␤ but not for thyroid hormone receptor, retinoid acid receptor, p53, or serum response factor (26) . Together, these results validate CAPER␣ as a new transcriptional coactivator for v-Rel.
CAPER␣'s N-terminal and central regions are involved in coactivation of v-Rel-mediated transcription. We used mutagenesis to identify the domains of CAPER␣ necessary for activation of NF-B-dependent transcription (Fig. 4A ). Similar to full-length CAPER␣, the two CAPER␣ fragments that were isolated in the two-hybrid screen (CAPER␣ 6 and 17) synergistically enhanced v-Rel-mediated transactivation of a luciferase reporter (Fig. 4B , bars 8 and 9). This suggested that the overlapping region between these fragments might be important for interaction of CAPER␣ with the v-Rel TAD (CAPER␣ amino acids 310 to 359). Surprisingly, however, a CAPER␣ mutant deleted of this putative vRID (⌬vRID) retained the ability to enhance v-Rel-mediated transactivation (Fig. 4C, bar 11 ). This suggests that additional sequences in CAPER␣ can promote its interaction with v-Rel. Conversely, a CAPER␣ mutant consisting of only the putative vRID failed to coactivate with v-Rel (bar 12). In fact, the vRID mutant reduced synergistic activation of IL-6-B-luciferase by CAPER␣ plus v-Rel, suggesting that it acts in a dominant-negative fashion (Fig. 4D , compare bar 6 with bars 4 and 5). Despite the modest inhibition seen in bar 6 versus 4, analysis by Student's t test showed that repression of CAPER-induced v-Rel coactivation by vRID is significant (P value of 0.028). Moreover, titration experiments showed that transfection of increasing amounts of vRID leads to inhibition of CAPER-induced v-Rel coactivation in a dose-dependent manner (Fig. 4E) . Since expression of vRID did not reduce the levels of CAPER␣-Flag (Fig. 4F) , these data support the conclusion that vRID acts in a dominant-negative fashion.
We then analyzed the activities of mutants comprised of the N-terminal or C-terminal region of CAPER␣ (N-CAPER␣ and CAPER␣-C) (Fig. 4A) . The N terminus of CAPER␣ extending up to the previously described c-Jun interaction domain (26) strongly enhanced v-Rel's transcriptional activity (N-CAPER␣, amino acids 1 to 291 (Fig. 5A , bar 3 versus bar 1). This mutant showed no dominant-negative effect when coexpressed with CAPER␣ (bar 7 versus bars 2 and 6). In contrast, a C-terminal mutant spanning from the end of the c-Jun Since the N-terminal region of CAPER␣ was necessary for synergistic activation with v-Rel, we examined whether it was also required for their interaction by coimmunoprecipitation in 293T cells cotransfected with v-Rel and Flag-tagged CAPER␣, mutant ⌬vRID, or N-CAPER␣. Mutant ⌬vRID coimmunoprecipitated with v-Rel, indicating that although amino acids 310 to 359, which overlap between CAPER␣ fragments 6 and 17, may be involved in CAPER␣'s interaction with v-Rel, they are not exclusively responsible for association with v-Rel (Fig.  5B, lanes 5 and 6) . Surprisingly despite its ability to coactivate v-Rel-mediated transcription, mutant N-CAPER␣ did not show significant interaction with v-Rel compared to its background immunoprecipitation with the preimmune control (Fig.  5B, lanes 8 and 9) . Of potential relevance in this regard, our studies revealed that CAPER␣ can form homodimers as seen by coimmunoprecipitation of Xpress-tagged CAPER␣ with either CAPER␣-Flag, ⌬vRID or, N-CAPER␣ (Fig. 5C, lanes 2,  4, and 9, and D, lanes 2, 5, and 8) . Although the amount of Xpress-CAPER coprecipitating with N-CAPER␣-Flag ap- peared to be significantly less than that with CAPER␣-Flag or ⌬vRID, reprobing with anti-Flag also revealed less efficient immunoprecipitation of N-CAPER␣-Flag (Fig. 5D ). In contrast to its association with these proteins, Xpress-CAPER␣ failed to associate with a Flag-Mcl-1 control (Fig. 5D, lane 11) . This suggests that the ability of N-CAPER␣ to coactivate vRel-mediated transcription may result from its ability to form dimers with endogenous CAPER␣. Together these results pinpoint an important role for the N-terminal and central regions of CAPER␣ in coactivating v-Rel-mediated transcription.
CAPER␣ antagonizes v-Rel's potent transforming activity. The human and chicken CAPER␣ proteins are highly related (69% identity) and are identical in the putative vRID region (Fig. 6A) . We thus investigated whether CAPER␣ influences v-Rel's potent transforming activity in primary chicken lymphocytes by coexpressing CAPER␣, mutant vRID, or an EGFP control along with v-Rel in primary CSCs, using a bicistronic avian retroviral vector driving v-Rel from an internal ribosome entry site (pUC19-pJD214-IRES-vRel). Immunoblots verified that v-Rel was expressed efficiently from all of these constructs, as were CAPER␣-Flag and EGFP (Fig. 6B , lanes 1 to 3, 9, and 11). Although the very small size of XpressvRID (ϳ9.5 kDa) precluded its detection by immunoblotting (data not shown), it displayed a dominant-negative effect in luciferase assays ( Fig. 4D and E) . Importantly, CAPER␣ dramatically inhibited v-Rel's transforming activity, as primary CSCs infected with CAPER␣-IRES-vRel rarely gave rise to transformed colonies (Fig. 6C) . This was in stark contrast to the EGFP-IRES-v-Rel control, which led to abundant colony formation. Moreover, the few colonies that arose from cells infected with CAPER␣-IRES-vRel did so with markedly delayed kinetics compared to the EGFP-IRES-vRel control (Fig.  6D) . Indeed, the soft agar medium of a single dish out of three containing cells expressing CAPER␣-IRES-vRel only began to acidify at day 14 postseeding, compared to day 6 to 7 in those expressing the EGFP-IRES-vRel control. Only two of the seven colonies that ever arose from CSCs infected with CAPER␣-IRES-vRel could be propagated in liquid culture, and both failed to express CAPER␣-Flag although they expressed v-Rel at levels equivalent to those in CSCs transformed by the EGFP-IRES-vRel control (Fig. 6B, lanes 4, 7, 8, 14, and 15 ). This indicates that CAPER␣ is detrimental to cell transformation by v-Rel.
In contrast to CAPER␣, the dominant-negative vRID mutant coexpressed with v-Rel transformed cells as efficiently as the EGFP-IRES-vRel control as measured by colony formation in soft agar (Fig. 6C) . In addition, vRID reproducibly accelerated the kinetics of cell transformation, as seen by faster acidification of the agar medium compared to the EGFP-IRES-vRel positive control (Fig. 6D) . Since v-Rel was expressed at equivalent levels in lymphoid cells transformed by all of these constructs (Fig. 6B, lanes 4 to 8) , these data indicate that CAPER␣ adversely affects cell transformation by v-Rel by interfering with initiation and/or maintenance of cell transformation, whereas the dominant-negative effect of mutant vRID is associated with accelerated kinetics of transformation.
CAPER␣ knockdown promotes colony formation by v-Reltransformed CSCs. In complementary studies, we investigated how endogenous CAPER␣ affects the transformed phenotype of established v-Rel-transformed CSCs by silencing endogenous chicken CAPER␣ with siRNA. Electroporation of siRNA 233 significantly knocked down endogenous chicken CAPER␣ compared to a nonspecific control siRNA (NC 1), as seen by RT-PCR (Fig. 7A) . Importantly, silencing of CAPER␣ reproducibly enhanced (ϳ3-fold) the ability of v-Rel-transformed CSCs to form colonies in soft agar compared to the NC 1 siRNA control (Fig. 7B) . This effect appeared to be specific, since siRNA 233 had no significant effect on the growth of control ALV-transformed chicken DT40 pre-B cells in soft agar (Fig. 7B) . Hence, reducing endogenous CAPER␣ levels selectively enhances the growth of v-Rel-transformed lymphocytes in soft agar, a phenotype that is a strong indicator of cell transformation. These results are consistent with our finding that dominant-negative vRID enhances the kinetics of v-Relmediated transformation (Fig. 6D) . This also validates our ------------------------------------EPIDNLTPEERDARTVFCMQLAARIRPRDLEEFFSTVGKVRDVRMISDRNSRRSKGIAYVEFVDVSSVPLAIGLTGQRVLGVPIIVQASQAEKNRAAAMAN Chicken ARLAEGTGLQIPPAAQQALQMSGSLAFGAVA LAAAASVQPLATQCFQLSNMFNPQTEEE GWDTEIKDDVIEECNKHGGVIHIYVDKNSAQ
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The N-terminal half of CAPER␣ has a serine-arginine-rich region similar to that found in a large group of factors involved in pre-mRNA splicing (amino acids 41 to 90). It also contains two of the three RNA recognition motifs found in CAPER␣ (amino acids 153 to 230, 250 to 328, and 445 to 508) (Fig. 4A) , which are typically implicated in protein-RNA or protein-protein interactions. These may allow CAPER␣ to interact with other factors to modulate transcription, mediate its association with v-Rel, and/or participate in CAPER␣ dimer formation. Indeed, we found that although mutant vRID had a dominantnegative effect on v-Rel coactivation by CAPER␣, deletion of amino acids 310 to 359 in mutant ⌬vRID did not eliminate its ability to associate with v-Rel and synergize its transcription. This suggests that although the putative vRID may participate in CAPER␣'s interaction with v-Rel, other sequences such as those found in the N terminus are likely to also be involved.
CAPER␣ coactivation of v-Rel-mediated transcription. CAPER␣ is a rather selective coactivator of certain transcription factors, and it synergized v-Rel-and AP-1-mediated transcription but failed to enhance transactivation by E2F1 in our assays. This agrees with prior work showing that CAPER␣ selectively coactivates transcription mediated by AP-1 and steroid hormone receptors but not that induced by thyroid hormone receptor, retinoid acid receptor, p53, or serum response factor (11, 26) . Its ability to synergistically enhance transcription by v-Rel and AP-1 is interesting, since both factors regulate the expression of genes involved in the oncogenic process and AP-1 can directly interact with Rel/NF-B to synergistically activate gene expression (42, 46) . Additionally, cJun is a transcriptional target of v-Rel and is essential as part of the AP-1 complex for v-Rel's ability to transform lymphocytes (15, 28) . Both c-Jun and JunB are aberrantly expressed in malignant Hodgkin/Reed-Sternberg cells of Hodgkin's lymphoma, which depend on Rel/NF-B for survival, and synergize with NF-B (37). It is thus tempting to speculate that CAPER␣ might help to integrate the transcriptional activities of Rel/NF-B and AP-1 on certain promoters. CAPER␣ was previously isolated by virtue of its interaction with the general coactivator ASC-2 (26), which interacts with multiple transcriptional regulators, including SRC-1, CBP/ p300, nuclear receptors, AP-1, and NF-B (31, 32) . While ASC-2 was previously shown to potentiate NF-B-driven transcription and relieve its trans-repression and that of AP-1 by nuclear hormone receptors (32) , CAPER␣ might coactivate transcription driven by v-Rel independently of ASC-2, since ASC-2 associates with the C terminus of CAPER␣, which is absent in N-CAPER␣ (amino acids 406 to 530) (Fig. 4A) (26) . In this scenario CAPER␣ would be likely to recruit different cofactors to enhance transcription mediated by AP-1, nuclear hormone receptors, and v-Rel. On the other hand, since N-CAPER␣ may coactivate v-Rel by forming heterodimers with endogenous CAPER␣, we do not rule out the possibility that ASC-2 might contribute to coactivation by CAPER␣ and vRel. Future studies will help to elucidate the mechanism by which CAPER␣ coactivates v-Rel-mediated transcription.
CAPER␣ inhibition of Rel's oncogenic activity. In addition to its effect on v-Rel-induced transcription, CAPER␣ strongly suppressed v-Rel's transforming activity. This is unlikely to result from overexpression artifacts, since coexpression of the dominant-negative mutant vRID consistently accelerated the kinetics of v-Rel-induced transformation. Additionally, endogenous CAPER␣ knockdown with siRNA markedly enhanced the transformed phenotype of v-Rel-transformed CSCs, as seen by colony formation in agar. These results agree with our coimmunoprecipitation data showing that only very low levels of v-Rel are found in complex with endogenous CAPER␣ in transformed CSCs (Fig. 2C) . This also agrees with the apparent selection that we observed against high-level expression of CAPER␣ in CSCs transformed by CAPER␣-IRES-vRel (Fig.  6B, lanes 14 and 15) . This antagonistic effect of CAPER␣ is unlikely to result from a global inhibitory effect on lymphocyte transformation, since silencing CAPER␣ with siRNA had no significant effect on the ability of ALV-transformed DT40 cells to form colonies in agar. These data rather support the notion that CAPER␣'s inhibitory effects are specific to Rel-mediated transformation.
Although the mechanism by which CAPER␣ antagonizes v-Rel's transforming activity is not fully understood, it is possible that transcriptional coactivation by CAPER␣ increases v-Rel's transactivation potency beyond an optimal level for cell transformation. Indeed work from Gilmore's group and ours unveiled an inverse correlation between the strength of the v-Rel-and c-Rel TADs and their transforming efficiency (12, 43, 44) . The fact that naturally occurring c-rel gene mutations in PMBCL and follicular lymphoma specimens decrease cRel's transactivation potency and enhance its transforming activity in chicken lymphocytes is also consistent with the idea that too much Rel transcriptional activity can be detrimental to cell transformation (45) . This raises the possibility that CAPER␣ might enhance Rel-induced activation of specific genes beyond an acceptable level and that this is detrimental to its oncogenic activity.
Alternatively, CAPER␣ might preclude efficient gene-specific repression by v-Rel, as recent reports from Bose's group and ours showed that v-Rel-induced downregulation of genes such as those for SH3BGRL and the B-cell receptor signaling molecules BLNK and BCAP is important for its transforming activity (19, 35) . While it remains to be determined whether CAPER␣ modulates expression of these or other Rel-regulated genes, it is conceivable that it compromises Rel's transforming activity by enhancing activation and/or dampening repression of specific Rel-regulated genes. Since CAPER␣ is a bifunctional protein that can also modulate alternative splicing, as seen in response to steroid hormone receptor activation (11) , it could also affect alternative splicing of genes important for cell transformation by v-Rel. Support for this idea stems from recent evidence that v-Rel can promote alternative splicing of TERT to produce full-length TERT, which is necessary in v-Rel-transformed lymphocytes (24) . In this scenario, CA-PER␣ might compromise production of full-length TERT, given its antagonistic effect on cell transformation. Future studies will help to elucidate the mechanism by which CA-PER␣ suppresses v-Rel's transforming activity.
Finally, our finding that inhibition of CAPER␣ enhances v-Rel's transforming activity agrees with preliminary data indicating that CAPER␣ knockdown in the Hodgkin ReedSternberg-derived cell line KM-H2 causes a significant reduction in the number of cells in G 0 /G 1 phase and a concomitant increase in cells accumulating in S and G 2 /M (data not shown). Since these cells depend on constitutive Rel/NF-B activity for proliferation and survival (20) , these results suggest a potential tumor suppressor role for CAPER␣ toward Rel's oncogenic activity. In summary, we uncovered a novel and functional interaction between the coactivator CAPER␣ and the Rel TAD that influences v-Rel's transcriptional activity and strongly affects its oncogenicity. Future studies aimed at understanding how CAPER␣ functions in this context will help to further elucidate how Rel/NF-B participates in the control of lymphoid cell survival, proliferation, and malignant transformation.
